Multicenter study for diagnosing hepatic steatosis using attenuation measurement (ATT); Comparison with PDFF (MRI-determined proton density fat fraction).

Conditions

Chronic liver disease

Yoshida Y, Kumada T, Hirooka M, Ogawa S, Yamahira M, Gotoh T, Kamada Y, Sumida Y, Shimizu M, Hiasa Y, Toyoda H, Barr RG, Ferraioli G.

2026-03-16

10.1007/s00535-026-02392-7

Comparison Between Attenuation Measurement and the Controlled Attenuation Parameter for the Assessment of Hepatic Steatosis Based on <scp>MRI</scp> Images

Tatsuya Gotoh, Takashi Kumada, Sadanobu Ogawa, Fumihiko Niwa, Hidenori Toyoda et al. (11 authors)

Liver International2024-12-144 citations

10.1111/liv.16210

iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.

Hirooka M, Ogawa S, Koizumi Y, Yoshida Y, Goto T, Yasuda S, Yamahira M, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Hiasa Y, Toyoda H, Kumada T.

2024-03-309 citations

10.1007/s00535-024-02096-w

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent ATT and PDFF within 3 months Patients with chronic liver disease including viral hepatitis, NAFLD, autoimmune hepatitis, primary biliary cholangitis, and so on Patients who can follow instructions such as breath-holding.

Exclusion criteria

Exclusion criteria: Patients without claustrophobia Patients without magnetic substance or tattoo Patients without pacemakers Patients judged as inappropriate for the study by the study responsibility (share) physician.

Design outcomes

Primary

Measure	Time frame
We assess the accuracy of ATT in assessing hepatic steatosis compared to PDFF	—

Secondary

Measure	Time frame
We verify whether ATT can diagnose fatty liver (liver fat content 5% or more)	—

Countries

Japan

Contacts

Public ContactTakashi Kumada

Gifu Kyoritsu University Department of Nursing, Faculty of Nursing

takashi.kumada@gmail.com+81584773512

Outcome results